Eli Lilly has announced substantial investments to expand its manufacturing capabilities in Ireland, with over $1 billion allocated to its Limerick facility and $800 million to its site in Kinsale. These expansions aim to significantly boost production capacities for essential biologic active
The launch of Richter BioLogics' state-of-the-art biopharmaceutical Current Good Manufacturing Practice (cGMP) facility in Bovenau, Germany marks a significant milestone for the company and the industry at large. Positioned as a forefront leader in advanced biopharmaceutical production, the new
Sanofi is gearing up to address the rising demand for its respiratory syncytial virus (RSV) antibody drug, Beyfortus, by leveraging a recently approved manufacturing line. The company's proactive measures aim to ensure that there is no repeat of last year's shortages, which created significant
Amid significant strategic shifts and infrastructural investments, KBI Biopharma has decided to discontinue mammalian drug substance manufacturing at its Geneva, Switzerland facility. This move comes following a period of substantial upgrades and expansion, signaling a concerted effort to
In a significant move that is set to reshape the biopharmaceutical landscape, Tanvex BioPharma is acquiring Bora Biologics, a subsidiary of Bora Pharmaceuticals. This strategic merger aims to amalgamate the strengths of two industry leaders, creating a formidable force in the global Contract
Enhancing Manufacturing Capabilities Novartis is making significant strides in its efforts to expand manufacturing capabilities to meet the growing demand for radiopharmaceutical therapies aimed at treating cancer. To achieve this, the company is not only expanding an existing facility in
